No menu items!
Home Innovation USFDA declares the Bengaluru-based scientist's medical invention a "breakthrough device"

USFDA declares the Bengaluru-based scientist’s medical invention a “breakthrough device”

A Bengaluru-based scientist has developed a device for the treatment of different types of cancer. The US Food and Drug Administration’s (USFDA) Centre for Devices and Radiological Health has declared this invention to be a “breakthrough device”.

The credit for this smart medical breakthrough idea goes to Rajah Vijay Kumar. He is the Chairman of Organization De Scalene, an innovative technology company which is also based in Bengaluru. He is a passionate researcher in the field of nanotechnology biophysics and sustainable energy.

His invention Cytotron took 30 years of hard work and dedication, a device for controlling the multiplying and spreading processes of cancerous cells. It prevents the abrupt growth of tissues useful for treating protein-linked disorders to encourage a healthy life. This invention is known to help with the treatment of protein-linked disorders and provides the best support against neoplastic disease. He plans to manufacture the device in India and supply to various parts of the world as it has now got approval from The Centre for Devices and Radiological Health and USFDA.


Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

How Robinhood makes money? Robinhood Business Model

Robinhood is a Fintech company that lets you trade for free. Robinhood disrupted the trading industry with its freemium business model. Robinhood...

Uber Business Model and Uber Revenue Model

The Uber App has made commuting much more comfortable with a tap on your phone thus gone are the days where we...

Zoom Business Model and success story, funding and growth

Zoom business model and zoom success story Once you read the word ZOOM, you might relate it to cars...

Abraham Hicks success story and biography facts

Abraham Hicks biographyBorn: March 5, 1948Home...

Recent Comments